A Double-Blind, Placebo-Controlled, Crossover Study of Magnesium Supplementation in Patients with XMEN Disease.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Hence, the researchers performed a randomized, double-blind, placebo-controlled, crossover study in 2 parts.

Who Took Part

According to the abstract, 2 patients were involved.

How the Study Was Run

The design is described as randomized, double-blind, open-label, placebo-controlled and crossover.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include CD8-Positive T-Lymphocytes, Cation Transport Proteins, Dietary Supplements, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Magnesium and Neoplasms.

Author keywords: Immunodeficiency, MAGT1, NKG2D, XMEN disease and congenital disorder of glycosylation.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Vitamin D, K2, Magnesium and Zinc in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2022 (Journal of clinical immunology), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.